Dermavant CEO draws Botox comparison to instill Vtama confidence amid slow psoriasis uptake

Dermavant CEO Todd Zavodnick isn’t concerned with the slow uptake of the hyped plaque psoriasis drug Vtama. He points to another breakthrough treatment which took a while to catch on: Botox.